Over consistency evaluation of 13 large varieties (list attached)

This week, all enterprises entered the harvest period of conformity evaluation According to incomplete statistics, 13 varieties / 17 products have passed the conformity evaluation To some extent, the battlefield of consistency evaluation has entered the white heat According to incomplete statistics, a total of 17 products of 13 varieties have passed the consistency evaluation this week, including many well-known pharmaceutical enterprises such as Shiyao group, Hengrui pharmaceutical, Yiling pharmaceutical and Shenzhen xinlitai pharmaceutical, many of which have passed the consistency evaluation (photo source: sapphire blue) Ouyi Pharmaceutical Co., Ltd., the group with the largest number of product specifications, has 4 varieties and 5 product specifications with consistency evaluation, of which ibuprofen granules (0.2g) is the first one Zhejiang Haizheng Pharmaceutical Co., Ltd and Shandong Lukang Pharmaceutical Co., Ltd have two product planning reviews: Haizheng pharmaceutical's anatrazole tablets (1mg) and letrozole tablets (2.5mg) have been reviewed for consistency It is worth noting that in letrozole tablets, Haizheng pharmaceutical is only one step later than Hengrui pharmaceutical, becoming the second one Up to now, 433 products have passed the (deemed) consistency evaluation, and 39 varieties have gathered more than three After combing, sepiland found that this week, there were six first consistency evaluations in the regulations, including ciprofloxacin hydrochloride tablets of Yiling pharmaceutical, ibuprofen granules of Shiyao group and amoxicillin capsule (0.25g according to c16h19n3o5s) of Shandong Lukang Pharmaceutical It is understood that Hengrui pharmaceutical and Haizheng pharmaceutical released the notice of over evaluation of letrozole tablets (2.5mg) on the same day, but Hengrui pharmaceutical announced that its letrozole tablets (2.5mg) were the first to pass the consistency evaluation, that is to say, Haizheng pharmaceutical was poor, only one step for Hengrui, which was the second over evaluation pharmaceutical enterprise According to the public information, the original manufacturer of letrozole tablets is Novartis, Switzerland, which was approved for listing in the United States in 1997 and approved for import in 2003 Manufacturers of the same variety in China, including Hengrui Pharmaceutical Co., Ltd and Haizheng Pharmaceutical Co., Ltd - all letrozole tablets listed in China have passed the consistency evaluation In addition, Beijing Yiling Bioengineering Technology Co., Ltd and Hainan Jinrui Pharmaceutical Co., Ltd applied for the new 4 categories, and Peili Pharmaceutical Co., Ltd applied for the 5 categories According to the data of mienei.com, in 2018, the sales of letrozole tablets in the terminals of public medical institutions in China exceeded 2 billion yuan Among them, Novartis market share reached 58.39%, Jiangsu Hengrui pharmaceutical accounted for 39.35%, and Zhejiang Haizheng pharmaceutical accounted for 2.26% Because of the large amount and wide use of this variety, and the absolute market share of the original research drug, it is likely to be included in the centralized purchase in the future, so a new round of brand change will be ushered in In addition to the first consistency evaluation of six product specifications, there are two product specifications that have been evaluated by three enterprises this week Levetiracetam (0.25g) is a new antiepileptic drug with new antiepileptic mechanism It is used in the treatment of partial seizures (with or without secondary generalized seizures) in adults and children over 4 years old, and in the treatment of generalized tonic clonic seizures in adults and adolescents over 16 years old It was first developed by UCB company in Belgium The consistency evaluation of xinlitai means that there are three enterprises that have been evaluated, namely, Zhejiang Jingxin, Zhejiang puluokangyu and xinlitai According to the data of minenet, the sales volume of levetiracetam in public hospitals nationwide in 2017 was 842 million yuan, with a market growth rate of 29.97% From the perspective of market structure, the original research enterprise's best time ratio accounts for 98.04% of the market, and the rest of the market is divided by domestic pharmaceutical enterprises such as xinlitai, Jingxin and shenghuaxi Cefalexin capsule (0.125g) is mainly used to treat acute tonsillitis, angina, sinusitis, bronchitis, pneumonia and other respiratory tract infections, otitis media, urinary tract infections and skin and soft tissue infections caused by sensitive bacteria In 2017, the sales volume of Cefalexin in China's public medical institutions was nearly 300 million yuan Among them, capsule occupies more than 60% market share Cypress blue searches for "Cefalexin" on the official website of China food and drug administration There are 741 approvals in total The market competition is quite fierce In terms of the current market pattern, Shandong Luoxin Pharmaceutical Co., Ltd has the largest market share, accounting for 33.96%; North China Pharmaceutical Co., Ltd Hebei Huamin Pharmaceutical Co., Ltd 16.74%; Shanghai Modern Pharmaceutical Co., Ltd 9.97%, ranking second and third.